Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen Extension Study (CS12)
NCT02052791Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2014
- Primary completion
- Jan 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoints: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events up to 24 Months, Number of participants with clinically significant neurological examination abnormalities up to 24 Months and 7 more. Started Jan 2014; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02052791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052791.